
About
PharmAI develops AI-based structure analysis software and discovery services for drug discovery. It works with pharmaceutical and biotech research teams on target identification, focused screening, scaffold diversification, and off-target prediction from its site in Dresden, Germany.
Services
Focused Library Service
Selects promising compounds for a target and screening library to turn high-throughput screening into focused screening.
Scaffold Diversification
Identifies analogue compounds and diversifies search spaces from millions of compounds to increase the diversity of possible hits.
Off-Target Identification
Predicts potential off-target proteins early in discovery using 3D protein structure data and AI.
Target Identification
Analyzes binding site geometry and interaction patterns to identify new scaffolds and targets.
DiscoveryEngine platform
Uses interpretable AI, deep learning, and structure-based modeling to screen compound spaces and rank candidate molecules.
DiscoveryEngine Nuc
Finds halogenated small molecules for radiopharmaceutical development.
- Turnaround
- Less than four weeks · a few weeks
- What to send
- Target · Screening library · Compound · Library of up to 2M compounds
Capabilities
- Assays and studies
- In vivo · Small molecules · HTS · In vitro validation · In vivo validation · Binding site analysis · Off-target prediction · High-throughput screening · Focused screening
- Scale and capacity
- 95% of the human proteome · 180 billion compounds · Over 40 projects
- Therapeutic areas
- Cancer · Malaria · Drug discovery · Radiopharmaceutical development
Instruments and platforms
- Protein Data Bank (PDB)
Modalities and species
- Modalities
- Small molecule · Antibody · Peptide
- Species and models
- Human proteome · PDE2 · MAPK14
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Company
- Founded
- 2019
Locations
- Based in
- Dresden, Germany
- Sites
- Dresden, Germany
Similar labs
Work here? Claim this listing